Alan Douglas Tice

Summary

Affiliation: University of Hawaii
Country: USA

Publications

  1. pmc Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment
    Nuntra Suwantarat
    Department of Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii 96813, USA
    Int J Med Sci 7:36-42. 2010
  2. doi Oritavancin: a new opportunity for outpatient therapy of serious infections
    Alan Tice
    Infections Limited Hawaii, Honolulu, Hawaii 96814, USA
    Clin Infect Dis 54:S239-43. 2012
  3. pmc Access to care: the physician's perspective
    Alan Tice
    Infections Limited Hawaii, Honolulu, Hawaii 96813, USA
    Hawaii Med J 70:33-8. 2011
  4. ncbi Viral hepatitis in Hawai'i--differing perspectives
    Alan D Tice
    University of Hawai i John A Burns School of Medicine, Honolulu, HI, USA
    Hawaii Med J 69:3-20. 2010
  5. pmc Quantitation of Staphylococcus aureus in seawater using CHROMagar SA
    Alan D Tice
    Department of Medicine, John A Burns School of Medicine, University of Hawai i at Manoa, Honolulu, HI, USA
    Hawaii Med J 69:8-12. 2010
  6. ncbi Knowledge of severe acute respiratory syndrome among community physicians, nurses, and emergency medical responders
    Alan Douglas Tice
    Department of Medicine, University of Hawaii, John A Burns School of Medicine, Honolulu, Hawaii 96813 2427, USA
    Prehosp Disaster Med 21:183-9. 2006
  7. ncbi Outpatient parenteral antimicrobial therapy for central nervous system infections
    A D Tice
    Infections Limited, P S, Tacoma, WA 98402, USA
    Clin Infect Dis 29:1394-9. 1999
  8. ncbi Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines
    Alan D Tice
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA
    Clin Infect Dis 38:1651-72. 2004
  9. ncbi Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy
    Alan D Tice
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
    J Antimicrob Chemother 53:ii83-6. 2004
  10. ncbi Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy
    Alan D Tice
    Infections Limited, P S, Tacoma, Washington, USA
    Am J Med 114:723-8. 2003

Collaborators

Detail Information

Publications19

  1. pmc Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment
    Nuntra Suwantarat
    Department of Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii 96813, USA
    Int J Med Sci 7:36-42. 2010
    ..To identify apparent adverse effects of treatment of chronic hepatitis C and their relationship to sustained virologic response (SVR)...
  2. doi Oritavancin: a new opportunity for outpatient therapy of serious infections
    Alan Tice
    Infections Limited Hawaii, Honolulu, Hawaii 96814, USA
    Clin Infect Dis 54:S239-43. 2012
    ....
  3. pmc Access to care: the physician's perspective
    Alan Tice
    Infections Limited Hawaii, Honolulu, Hawaii 96813, USA
    Hawaii Med J 70:33-8. 2011
    ..This was likely related to the more favorable impressions of the services, payments, and lower administrative burden offered by those companies compared with others...
  4. ncbi Viral hepatitis in Hawai'i--differing perspectives
    Alan D Tice
    University of Hawai i John A Burns School of Medicine, Honolulu, HI, USA
    Hawaii Med J 69:3-20. 2010
    ....
  5. pmc Quantitation of Staphylococcus aureus in seawater using CHROMagar SA
    Alan D Tice
    Department of Medicine, John A Burns School of Medicine, University of Hawai i at Manoa, Honolulu, HI, USA
    Hawaii Med J 69:8-12. 2010
    ..A more rapid protocol, utilizing a 4-hour tube coagulase confirmatory test, enables a 48-hour turnaround time with a modest false negative rate of less than 10%...
  6. ncbi Knowledge of severe acute respiratory syndrome among community physicians, nurses, and emergency medical responders
    Alan Douglas Tice
    Department of Medicine, University of Hawaii, John A Burns School of Medicine, Honolulu, Hawaii 96813 2427, USA
    Prehosp Disaster Med 21:183-9. 2006
    ..In order to determine the knowledge of these clinicians, a survey of their understanding of SARS and their use of educational resources was administered...
  7. ncbi Outpatient parenteral antimicrobial therapy for central nervous system infections
    A D Tice
    Infections Limited, P S, Tacoma, WA 98402, USA
    Clin Infect Dis 29:1394-9. 1999
    ..The antimicrobial used was changed in 13 cases (19%) because of an adverse effect or clinical failure. OPAT can be safe and effective for patients with CNS infections, but patients must be carefully selected and monitored closely...
  8. ncbi Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines
    Alan D Tice
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA
    Clin Infect Dis 38:1651-72. 2004
  9. ncbi Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy
    Alan D Tice
    John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
    J Antimicrob Chemother 53:ii83-6. 2004
    ..Ertapenem should be added to the growing list of once-daily parenteral antibiotics that can be given to outpatients...
  10. ncbi Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy
    Alan D Tice
    Infections Limited, P S, Tacoma, Washington, USA
    Am J Med 114:723-8. 2003
    ..To examine the effects of diabetes, vascular disease, age, and antimicrobial therapy on clinical outcomes, including amputation rates, in patients with osteomyelitis treated in the outpatient setting...
  11. ncbi Risk factors and treatment outcomes in osteomyelitis
    Alan D Tice
    Infections Limited, P S, Tacoma, WA, USA
    J Antimicrob Chemother 51:1261-8. 2003
    ..03). Treatment with ceftriaxone was as effective as the penicillinase-resistant penicillins and cefazolin...
  12. ncbi Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins
    A D Tice
    University of Washington, Seattle, USA
    Drugs 59:29-35; discussion 47-9. 2000
    ..In order to achieve cost savings, managed care will increasingly rely on home and outpatient therapy. This pressure will need to be counterbalanced by quality assurance programmes and outcomes measurements...
  13. ncbi The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries
    A Tice
    University of Washington School of Medicine, Seattle, Wash, USA
    Chemotherapy 47:5-16. 2001
    ..Data collected by the OPAT Outcomes Registry confirms that osteomyelitis can be safely and effectively treated with intravenous antibiotics outside the hospital...
  14. ncbi Cost perspectives for outpatient intravenous antimicrobial therapy
    Alan D Tice
    Outpatient Parenteral Antibiotic Therapy OPAT, Outcomes Registry, Tacoma, Washington 98402, USA
    Pharmacotherapy 22:63S-70S. 2002
    ..We found that the cost of outpatient therapy was substantial, although nonuniform, across payer types. Alternative outpatient therapies associated with lower risks for adverse events and lower costs should be considered...
  15. ncbi Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial
    Benjamin A Lipsky
    Veterans Affairs Puget Sound Health Care System, University of Washington School of Medicine, Seattle, WA 98108 1597, USA
    Int Wound J 4:30-8. 2007
    ..Increased white blood cell count and severe UT wound grade at baseline, but not other features, were significant independent and additive risk factors for clinical failure in patients treated for a diabetic foot infection...
  16. ncbi Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections
    Alan D Tice
    John A Burns School of Medicine, University of Hawaii, Honolulu, USA
    Am J Health Syst Pharm 64:1080-6. 2007
    ..To evaluate potential cost savings, trial data were used to determine the clinical outcomes for i.v. ertapenem given once daily and i.v. piperacillin-tazobactam given every six hours daily in treating diabetic foot infections...
  17. ncbi Survey of methicillin-resistant Staphylococcus aureus (MRSA) carriage in healthy college students, Hawai'i
    Jennifer E Morita
    Department of Microbiology, Kapi olani Community College, Honolulu, HI 96816, USA
    Hawaii Med J 66:213-5. 2007
    ..Additional testing of a larger group of healthy individuals would be beneficial in assessing factors associated with CA-MRSA and Methicillin-susceptible Staphylococcus aureus (MSSA) carriage in Hawai'i...
  18. ncbi Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial
    Benjamin A Lipsky
    University of Washington School of Medicine and Veterans Affairs Puget Sound Health Care System S 111 GIMC, 1660 S Columbian Way, Seattle, WA 98108, USA
    Lancet 366:1695-703. 2005
    ..Our aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infections...
  19. ncbi Bloodborne pathogen exposure and recommendations for management
    Alan D Tice
    Department of Internal Medicine, John A Burns School of Medicine, University of Hawaii, USA
    J Infus Nurs 25:S5-9. 2002
    ..This article will focus on those agents as they pose the greatest known threats and offer the potential for intervention...